No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Shares in Oxford Biomedica tanked by a quarter on Friday after the cell and gene therapy manufacturer slashed its full year revenue and margins forecast citing shortterm client ordering delays, programme deferrals and operational delays at its North Carolina facility.
The company now expects 2026 revenue of 180m-200m compared with prior guidance of 220-240m.
Full-year EBITDA margin is expected to be mid-single-digit percentage - excluding one off costs - and low-single-digit on a reported basis, compared with the 10% guidance provided in March, reflecting lower than expected revenues and therefore absorption of operating costs.
Reporting by Frank Prenesti for Sharecast.com
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.